SynthesisFrontiers in immunology2026
Occurrence and clinical course of immune checkpoint inhibitor-associated inflammatory arthritis and polymyalgia rheumatica-like syndromes: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) and polymyalgia rheumatica (PMR)-like syndromes are clinically important rheumatic immune-related adverse events, but definitions vary across studies. We estimated their occurrence in real-world cohorts and summarized clinical course and management. Methods: PubMed, Ovid MEDLINE, Embase, Web of Science Core Collection, and Cochrane CENTRAL were searched from inception through July 25, 2026. Two reviewers independently screened studies, extracted data, and assessed risk of bias, with disagreements resolved by a third reviewer. Compatible single-group proportions were pooled using random-intercept binomial generalized linear mixed models; non-poolable clinical-course evidence was synthesized using the Synthesis Without Meta-analysis framework. Results: Sixty-five reports representing 63 studies were included. Five independent ICI-treated cohorts reported 140 study-defined Conclusion: In denominator-valid studies, approximately 3% of ICI-treated patients were classified as having Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261460334, identifier CRD420261460334.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.